{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:08:21Z","timestamp":1780319301345,"version":"3.54.1"},"reference-count":70,"publisher":"Medicinska Naklada d.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiat Danub"],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.24869\/psyd.2024.174","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T01:24:37Z","timestamp":1721179477000},"page":"174-184","source":"Crossref","is-referenced-by-count":1,"title":["CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS"],"prefix":"10.24869","volume":"36","author":[{"name":"Erasme Hospital \u2013 Universit\u00e9 Libre de Bruxelles (ULB), Faculty of Medicine, Department of Adult Psychiatry, Brussels, Belgium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kaiserman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vanderijst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Universit\u00e9 Libre de Bruxelles (ULB), Faculty of Medicine, Laboratory of Medical Psychology and Addictology. Brussels, Belgium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kornreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Brugmann Hospital \u2013 Universit\u00e9 Libre de Bruxelles (ULB), Faculty of Medicine, Department of Adult Psychiatry, Brussels, Belgium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6768","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"ref0","unstructured":"1. Aaronson, S. T. (2022). The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression (NCT04433845). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04433845"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Pont\u00e9, K. L., Guss, J., et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166. https:\/\/doi.org\/10.1177\/0269881119897615","DOI":"10.1177\/0269881119897615"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Akil, H., Gordon, J., Hen, R., Javitch, J., Mayberg, H., McEwen, B., et al. (2018). Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience & Biobehavioral Reviews, 84, 272-288. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.08.019","DOI":"10.1016\/j.neubiorev.2017.08.019"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Arrieta, O., Angulo, L. P., N\u00fa\u00f1ez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O., Mart\u00ednez-L\u00f3pez, D., et al. (2013). Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Annals of Surgical Oncology, 20(6), 1941-1948. https:\/\/doi.org\/10.1245\/s10434-012-2793-5","DOI":"10.1245\/s10434-012-2793-5"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Calder, A. E., & Hasler, G. (2023). Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology, 48(1), 104-112. https:\/\/doi.org\/10.1038\/s41386-022-01389-z","DOI":"10.1038\/s41386-022-01389-z"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., et al. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399-408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x","DOI":"10.1007\/s00213-017-4771-x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., et al. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725-731. https:\/\/doi.org\/10.1177\/0269881118754710","DOI":"10.1177\/0269881118754710"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews, 71(3), 316-344. https:\/\/doi.org\/10.1124\/pr.118.017160","DOI":"10.1124\/pr.118.017160"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402-1411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1056\/NEJMoa2032994"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Carvalho, A. F., Sharma, M. S., Brunoni, R. R., Vieta, E., & Fava, G. A. (2016). The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and Psychosomatics, 85(5), 270-288. https:\/\/doi.org\/10.1159\/000447034","DOI":"10.1159\/000447034"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Celada, P., Puig, M. V., D\u00edaz-Mataix, L., & Artigas, F. (2008). The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biological Psychiatry, 64(5), 392-400. https:\/\/doi.org\/10.1016\/j.biopsych.2008.03.013","DOI":"10.1016\/j.biopsych.2008.03.013"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., & Goldhirsch, A. (2000). Depression and degree of acceptance of adjuvant cytotoxic drugs. The Lancet, 356(9238), 1326-1327. https:\/\/doi.org\/10.1016\/S0140-6736(00)02819-2","DOI":"10.1016\/S0140-6736(00)02821-X"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Conway, C. R., George, M. S., & Sackeim, H. A. (2017). Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. JAMA Psychiatry, 74(1), 9-10. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.2514","DOI":"10.1001\/jamapsychiatry.2016.2586"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., et al. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481-489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Daws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wall, M. B., Erritzoe, D., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 844-851. https:\/\/doi.org\/10.1038\/s41591-022-01744-x","DOI":"10.1038\/s41591-022-01744-z"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Dinis-Oliveira, R. J. (2017). Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews, 49(1), 84-91. https:\/\/doi.org\/10.1080\/03602532.2016.1278228","DOI":"10.1080\/03602532.2016.1278228"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018). Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chemical Neuroscience, 9(10), 2408-2427. https:\/\/doi.org\/10.1021\/acschemneuro.8b00155","DOI":"10.1021\/acschemneuro.8b00155"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637-1648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","DOI":"10.1056\/NEJMoa2206443"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Greenberg, P. E., Fournier, A. A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The economic burden of adults with major depressive disorder in the United States (2005 and 2010). Journal of Clinical Psychiatry, 76(2), 155-162. https:\/\/doi.org\/10.4088\/JCP.14m09298","DOI":"10.4088\/JCP.14m09298"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649-665. https:\/\/doi.org\/10.1007\/s00213-011-2358-5","DOI":"10.1007\/s00213-011-2358-5"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. https:\/\/doi.org\/10.1177\/0269881116675513","DOI":"10.1177\/0269881116675513"},{"key":"ref23","unstructured":"24. Grinspoon, L., & Bakalar, J. B. (1981). The psychedelic drug therapies. Current Psychiatric Therapies, 20, 275-283."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71-78. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"issue":"3","key":"ref25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","unstructured":"26. Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (1973). LSD-assisted psychotherapy in patients with terminal cancer. International Pharmacopsychiatry, 8(3), 129-144.","journal-title":"International Pharmacopsychiatry"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., et al. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151-158. https:\/\/doi.org\/10.1177\/02698811211073759","DOI":"10.1177\/02698811211073759"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. https:\/\/doi.org\/10.1016\/j.bbr.2014.04.016","DOI":"10.1016\/j.bbr.2014.04.016"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Halpern, J. H., & Pope, H. G. (1999). Do hallucinogens cause residual neuropsychological toxicity? Drug and Alcohol Dependence, 53(3), 247-256. https:\/\/doi.org\/10.1016\/S0376-8716(98)00140-6","DOI":"10.1016\/S0376-8716(98)00129-X"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Halpern, J. H., Lerner, A. G., & Passie, T. (2018). A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Current Topics in Behavioral Neurosciences, 36, 333-360. https:\/\/doi.org\/10.1007\/7854_2016_457","DOI":"10.1007\/7854_2016_457"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Halpern, J. H., & Pope, H. G., Jr. (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109-119. https:\/\/doi.org\/10.1016\/S0376-8716(02)00306-X","DOI":"10.1016\/S0376-8716(02)00306-X"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Hengartner, M. P., & Pl\u00f6derl, M. (2018). Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter! Frontiers in Psychiatry, 9, 517. https:\/\/doi.org\/10.3389\/fpsyt.2018.00517","DOI":"10.3389\/fpsyt.2018.00517"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Holland, J. C. (2013). Distress screening and the integration of psychosocial care into routine oncologic care. Journal of the National Comprehensive Cancer Network, 11(6), 687-690. https:\/\/doi.org\/10.6004\/jnccn.2013.0084","DOI":"10.6004\/jnccn.2013.0084"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3), 734-740. https:\/\/doi.org\/10.1007\/s13311-017-0542-y","DOI":"10.1007\/s13311-017-0542-y"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Johnson, M. W. (2018). Psychiatry might need some psychedelic therapy. International Review of Psychiatry, 30(4), 285-290. https:\/\/doi.org\/10.1080\/09540261.2018.1534780","DOI":"10.1080\/09540261.2018.1509544"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Kast, E. (1967). Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly, 41(4), 646-657. https:\/\/doi.org\/10.1007\/BF01575709","DOI":"10.1007\/BF01575709"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Kirsch, I. (2014). Antidepressants and the Placebo Effect. Zeitschrift f\u00fcr Psychologie, 222(3), 128-134. https:\/\/doi.org\/10.1027\/2151-2604\/a000176","DOI":"10.1027\/2151-2604\/a000176"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Kraehenmann, R., Pokorny, D., Aicher, H., Preller, K. H., Pokorny, T., Bosch, O. G., et al. (2017). LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Frontiers in Pharmacology, 8, 814. https:\/\/doi.org\/10.3389\/fphar.2017.00814","DOI":"10.3389\/fphar.2017.00814"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Krebs, T. S., & Johansen, P. \u00d8. (2013). Psychedelics and mental health: a population study. PLoS ONE, 8(8), e63972. https:\/\/doi.org\/10.1371\/journal.pone.0063972","DOI":"10.1371\/journal.pone.0063972"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Lebedev, A. V., L\u00f6vd\u00e9n, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping, 36(8), 3137-3153. https:\/\/doi.org\/10.1002\/hbm.22833","DOI":"10.1002\/hbm.22833"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Liechti, M. E. (2017). Modern Clinical Research on LSD. Neuropsychopharmacology, 42(11), 2114-2127. https:\/\/doi.org\/10.1038\/npp.2017.86","DOI":"10.1038\/npp.2017.86"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry, 18, 245. https:\/\/doi.org\/10.1186\/s12888-018-1824-6","DOI":"10.1186\/s12888-018-1824-6"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. Mintz, K. T., Gammer, B., Khan, A. J., Shaub, G., Levine, S., & Sisti, D. (2022). Physical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice. Frontiers in Psychiatry, 13, 914458. https:\/\/doi.org\/10.3389\/fpsyt.2022.914458","DOI":"10.3389\/fpsyt.2022.914458"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Mitchell, A. J., Vahabzadeh, A., & Magruder, K. (2011). Screening for distress and depression in cancer settings: 10 lessons from 40 years of primary-care research. Psycho-Oncology, 20(6), 572-584. https:\/\/doi.org\/10.1002\/pon.1928","DOI":"10.1002\/pon.1928"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Munkholm, K., Paludan-M\u00fcller, A. S., & Boesen, K. (2019). Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open, 9(6), e024886. https:\/\/doi.org\/10.1136\/bmjopen-2018-024886","DOI":"10.1136\/bmjopen-2018-024886"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021). Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology, 14(9), 1133-1152. https:\/\/doi.org\/10.1080\/17512433.2021.1948229","DOI":"10.1080\/17512433.2021.1933434"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as Medicines: An Emerging New Paradigm. Clinical Pharmacology & Therapeutics, 101(2), 209-219. https:\/\/doi.org\/10.1002\/cpt.557","DOI":"10.1002\/cpt.557"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565. https:\/\/doi.org\/10.1016\/S0140-6736(10)61462-6","DOI":"10.1016\/S0140-6736(10)61462-6"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49. Nutt, D., Spriggs, M., & Erritzoe, D. (2023). Psychedelics therapeutics: What we know, what we think, and what we need to research. Neuropharmacology, 223, 109257. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109257","DOI":"10.1016\/j.neuropharm.2022.109257"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50. Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., et al. (2022). Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology, 36(1), 31-45. https:\/\/doi.org\/10.1177\/02698811211043306","DOI":"10.1177\/02698811211066709"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51. Pinquart, M., & Duberstein, P. R. (2010). Depression and cancer mortality: a meta-analysis. Psychological Medicine, 40(11), 1797-1810. https:\/\/doi.org\/10.1017\/S003329170999207X","DOI":"10.1017\/S0033291709992285"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52. Posternak, M. A., & Zimmerman, M. (2005). Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry, 66(2), 148-158. https:\/\/doi.org\/10.4088\/JCP.v66n0202","DOI":"10.4088\/JCP.v66n0202"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53. Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., St\u00e4mpfli, P., et al. (2017). The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Current Biology, 27(3), 451-457. https:\/\/doi.org\/10.1016\/j.cub.2016.12.030","DOI":"10.1016\/j.cub.2016.12.030"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. Prieto, J. M., Blanch, J., Atala, J., Carreras, E., Rovira, M., Cirera, E., et al. (2002). Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. Journal of Clinical Oncology, 20(7), 1907-1917. https:\/\/doi.org\/10.1200\/JCO.2002.07.031","DOI":"10.1200\/JCO.2002.07.101"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55. Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., et al. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 177(5), 391-410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56. Richards, W. A., Rhead, J. C., Dileo, F. B., Yensen, R., & Kurland, A. A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9(1), 1-10. https:\/\/doi.org\/10.1080\/02791072.1977.10472021","DOI":"10.1080\/02791072.1977.10472021"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57. Rieser, N. M., Herdener, M., & Preller, K. H. (2022). Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. Current Topics in Behavioral Neurosciences, 56, 187-211. https:\/\/doi.org\/10.1007\/7854_2022_317","DOI":"10.1007\/7854_2022_317"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58. Roscoe, J., & Lozy, O. (2022). Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Science, Policy and Law, 8. https:\/\/doi.org\/10.1177\/20503245221085222","DOI":"10.1177\/20503245221085222"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59. Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology, 33(9), 1076-1087. https:\/\/doi.org\/10.1177\/0269881119855974","DOI":"10.1177\/0269881119855974"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180. https:\/\/doi.org\/10.1177\/0269881116675512","DOI":"10.1177\/0269881116675512"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200-218. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62. Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports, 7, 46421. https:\/\/doi.org\/10.1038\/srep46421","DOI":"10.1038\/srep46421"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258-272. https:\/\/doi.org\/10.1177\/02698811211069100","DOI":"10.1177\/02698811211069100"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Shim, E. J., & Park, J. H. (2012). Suicidality and its associated factors in cancer patients: results of a multi-center study in Korea. International Journal of Psychiatry in Medicine, 43(4), 381-403. https:\/\/doi.org\/10.2190\/PM.43.4.g","DOI":"10.2190\/PM.43.4.g"},{"key":"ref64","unstructured":"65. Stamets, P. (1996). Psilocybin Mushrooms of the World. Ten Speed Press."},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"66. Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE, 7(2), e30800. https:\/\/doi.org\/10.1371\/journal.pone.0030800","DOI":"10.1371\/journal.pone.0030800"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.12788\/jfp.0140","article-title":"Strategies for Optimizing the Treatment of Major Depressive Disorder","author":"Thase","year":"2021","unstructured":"67. Thase, M. E. (2021). Strategies for Optimizing the Treatment of Major Depressive Disorder. Journal of Family Practice, 70(1 suppl [iii]), S11-S19.","journal-title":"Journal of Family Practice 70(1 suppl [iii]) S11-S19"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"68. van Elk, M., & Yaden, D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews, 140, 104793. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104793","DOI":"10.1016\/j.neubiorev.2022.104793"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"69. Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K., & Stamatakis, E. A. (2020). Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. NeuroImage, 220, 117049. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.117049","DOI":"10.1016\/j.neuroimage.2020.117049"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"70. von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., et al. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","DOI":"10.1016\/j.eclinm.2022.101809"}],"container-title":["PSYCHIATRIA DANUBINA"],"original-title":["CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS"],"link":[{"URL":"https:\/\/psychiatria-danubina.com\/UserDocsImages\/pdf\/dnb_vol36_no2\/dnb_vol36_no2_174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:22:49Z","timestamp":1780316569000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatria-danubina.com\/UserDocsImages\/pdf\/dnb_vol36_no2\/dnb_vol36_no2_174.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,7,17]]}},"URL":"https:\/\/doi.org\/10.24869\/psyd.2024.174","relation":{},"ISSN":["0353-5053"],"issn-type":[{"value":"0353-5053","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}